'Clopidogrel loading' presentation slideshows

Optimal Angioplasty Pharmacology in 2006 : is there a continuing need for GP IIbIIIa inhibitors?

Optimal Angioplasty Pharmacology in 2006 : is there a continuing need for GP IIbIIIa inhibitors? Tony Gershlick Leicester UK AA 2006. Advisory Board :Speakers Bureau : Meeting sponsorships Eli Lilly :The Medicines Company: BMS : Sanofi No direct financial conflicts of interest.

1.09k views • 92 slides

?????? ?????? ????? ?????? ?????? ??????? ????? ????? ????????

?????? ?????? ????? ?????? ?????? ??????? ????? ????? ????????. ????' ??? ?? ???? ????? ???????? ?? " ? ?????, ???? ????? ????. 3 Major systems involved in thrombosis and hemostasis. Vessel wall Endothelium Platelets Coagulation cascade.

797 views • 60 slides

Antiplatelet therapy and PCI in unstable angina and NSTEMI

747 views • 42 slides

Objective

Objective. To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity after a 600 mg loading of the drug is predictive of drug-eluting stent thrombosis and cardiac mortality at long-term follow-up. Background.

277 views • 14 slides